Free 24-hour delivery over £60 · Same-day despatchOrder before 2pm - same-day despatch · Free 24-hour delivery over £60
Research use only
All lyophilised (powdered) products and any related items sold by Kovalabs are strictly for scientific research purposes. No dosing guidelines are supplied with any product. We comply with all local regulations governing research-only sales within the United Kingdom. We are not a pharmacy and do not endorse, offer, or provide advice for human or animal consumption. International customers are responsible for checking their own local laws and regulations before purchasing.
You must be 18 or over and purchasing for scientific research only.
By clicking ‘I agree’ you confirm you have read and accepted the terms set out in this disclaimer.
Research use only
· 6 min read
Search for a "retatrutide pen" and you have not asked a question about the molecule at all; you have asked a question about packaging. It is worth answering plainly, because the format you encounter says more about the seller than about the molecule. Retatrutide itself (developer code LY3437943) is one defined compound; what differs is packaging. Some sellers market it in pre-filled or refillable injector pens; research suppliers, Kovalabs included, supply it as a lyophilised vial. This page explains the difference at the supply level and why we have chosen the vial. It is supplied strictly as a research reagent; nothing here describes administration, dosing or any human use, and we neither supply nor endorse injection devices of any kind.
At the level of what you receive, there are two broad formats in circulation:
The distinction matters because the two are not the same kind of thing. One is a research chemical with documentation; the other is a piece of administration hardware. They answer different questions, and only one of them is a compound a laboratory can verify.
The choice is deliberate, and it comes down to what a research supplier should actually be responsible for: the compound, not the machinery.
So when the search starts at "retatrutide pen" and ends at an informed decision, the vial is usually the answer for anyone who cares about knowing what they have. That is a supply-and-quality argument, not a comment on use of any kind.
Whatever the format, the molecule is the same. Retatrutide (LY3437943) is a single-chain peptide with the verified identifiers below; the full chemistry, mechanism and trial-programme detail is in the dedicated retatrutide research reference.
| Compound | Retatrutide (LY3437943) |
|---|---|
| Class / mechanism | Triple GIP / GLP-1 / glucagon receptor agonist (by receptor pharmacology) |
| Molecular formula | C221H342N46O68 |
| Molecular weight | 4731 g/mol (average) |
| CAS number | 2381089-83-2 |
| PubChem CID | 171390338 |
| Supply format (Kovalabs) | Lyophilised vial, research use only |
Retatrutide has been studied in a registered clinical-trial programme, described here by study design and endpoint name only - no result is reproduced. Jastreboff et al. (N Engl J Med, 2023; PMID 37366315) was a randomised, double-blind, placebo-controlled phase 2 trial of the triple receptor agonist; Rosenstock et al. (Lancet, 2023; PMID 37385280) was a randomised, double-blind, placebo-controlled phase 2 trial in a type 2 diabetes study population. These are named as study designs only; the full design-and-endpoint treatment, with the neutralising guards, is in the retatrutide research reference. Listed as research context, not as findings a reader should expect.
Kovalabs supplies retatrutide as a lyophilised vial, strictly as a research chemical for laboratory research use only. It is not a medicine, supplement or veterinary product, is not for human or veterinary use, and nothing on this page constitutes a medicinal, therapeutic, efficacy, dosing or human-outcome claim. Kovalabs does not supply, fill, recommend or endorse injection pens or any administration device. Retatrutide has not been evaluated by the MHRA or any comparable regulator for safety or efficacy in humans or animals outside its clinical-trial setting. Every batch is third-party tested with a certificate of analysis. Full terms are on the research disclaimer page.
No. Kovalabs supplies retatrutide as a lyophilised research vial only. We do not supply, fill or endorse injector pens or any administration device. Pen-format devices are marketed by other sellers online; our focus is on supplying the verified compound itself.
A vial is the compound - lyophilised powder whose identity and purity can be verified against a certificate of analysis. A pen is a self-contained injector device, a piece of administration hardware rather than the compound. For research supply the vial is the standard format because it is the material and it is verifiable. This is a format and supply distinction, not a comment on use.
Because a research supplier should be responsible for the compound, not the delivery device. The vial is third-party tested and identity-verifiable, it puts the value into the peptide rather than a moulded device, and it keeps the laboratory reconstitution workflow flexible. See the reconstitution guide for the standard bench workflow.
Retatrutide (LY3437943): molecular formula C221H342N46O68, average molecular weight 4731 g/mol, CAS 2381089-83-2, PubChem CID 171390338. Full chemistry and the trial programme are in the retatrutide research reference.
No. It is supplied as a research chemical for laboratory use only, is not approved as a medicine by the MHRA or any comparable regulator, and is not for human or veterinary use. Nothing on this page is a medicinal, therapeutic or efficacy claim. See the research disclaimer for full terms.
The publication titles below are the original authors' own titles, reproduced so each citation can be verified against PubMed and the cited DOI. They are not statements, conclusions or claims by Kovalabs, and the body of this page describes each study by its design and endpoint name only.